Literature DB >> 29915864

[Acute exacerbation of chronic CLL with multiple pathological fractures : A rarity].

T Zafeiris1, M Gothner2, C Hempel Overhage3, G Heil3, B Roetman4.   

Abstract

Chronic lymphatic leukaemia (CLL) is one of the most common leukaemic diseases in middle Europe. Pathological fractures are rare findings in patients with CLL. The diagnosis of CLL is in most cases an incidental finding as it often stays asymptomatic for years. This article presents an interesting case of a 65-year-old male patient with known asymptomatic CLL for 5 years and fractures of the proximal femur and proximal radius after trauma. During the hospital stay the patient suffered multiple pathological fractures with histological findings of bony infiltration of the CLL and an acute phase, which was treated by combination chemotherapy.

Entities:  

Keywords:  Chemotherapy; Chronic lymphatic leukaemia; Osteolyses; Pathological fractures; Treatment

Mesh:

Year:  2018        PMID: 29915864     DOI: 10.1007/s00113-018-0517-4

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  11 in total

1.  Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur.

Authors:  T Robak; M Kasznicki; J Bartkowiak; R Kordek; E Wawrzyniak; J Z Błonski
Journal:  Leuk Lymphoma       Date:  2001-08

Review 2.  Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.

Authors:  Sonja Sorensen; Mark Wildgust; Nishan Sengupta; Cristina Trambitas; Joris Diels; Suzy van Sanden; Yingxin Xu; Emily Dorman
Journal:  Clin Ther       Date:  2017-01-03       Impact factor: 3.393

Review 3.  Present and future of personalized medicine in CLL.

Authors:  Emili Montserrat; Tycho Bauman; Julio Delgado
Journal:  Best Pract Res Clin Haematol       Date:  2016-08-12       Impact factor: 3.020

Review 4.  [Metastatic disease in long bones : Review of surgical treatment options].

Authors:  Franz Liska; Philipp Schmitz; Norbert Harrasser; Peter Prodinger; Hans Rechl; Rüdiger von Eisenhart-Rothe
Journal:  Unfallchirurg       Date:  2018-01       Impact factor: 1.000

5.  Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.

Authors:  Hong Liu; Melissa J Michmerhuizen; Yanbin Lao; Katty Wan; Ahmed Hamed Salem; James Sawicki; Michael Serby; Srirajan Vaidyanathan; Shekman L Wong; Suresh Agarwal; Martin Dunbar; Jens Sydor; Sonia M de Morais; Anthony J Lee
Journal:  Drug Metab Dispos       Date:  2016-12-19       Impact factor: 3.922

6.  [Analysis of 2000 surgically treated proximal femoral fractures : Multiple variables influence mortality].

Authors:  Franz Müller; Michael Galler; Tanja Kottmann; Michael Zellner; Christian Bäuml; Bernd Füchtmeier
Journal:  Unfallchirurg       Date:  2018-07       Impact factor: 1.000

7.  Pathological fractures in a patient with chronic lymphatic leucaemia without disease progression.

Authors:  Jasper C M Langenberg; Willem-Maarten Bosman; Jephta van den Bremer; Ewan D Ritchie
Journal:  BMJ Case Rep       Date:  2015-02-25

Review 8.  The investigation and management of suspected malignant pathological fractures: a review for the general orthopaedic surgeon.

Authors:  D J Bryson; L Wicks; R U Ashford
Journal:  Injury       Date:  2015-07-29       Impact factor: 2.586

9.  Chronic lymphocytic leukemia (CLL) terminating in multiple myeloma: report of two cases.

Authors:  R H Kough; A Z Makary
Journal:  Blood       Date:  1978-09       Impact factor: 22.113

10.  Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology.

Authors:  Graça M Dores; William F Anderson; Rochelle E Curtis; Ola Landgren; Evgenia Ostroumova; Elizabeth C Bluhm; Charles S Rabkin; Susan S Devesa; Martha S Linet
Journal:  Br J Haematol       Date:  2007-10-17       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.